{"id":407184,"date":"2021-01-04T06:03:27","date_gmt":"2021-01-04T11:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407184"},"modified":"2021-01-04T06:03:27","modified_gmt":"2021-01-04T11:03:27","slug":"neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/","title":{"rendered":"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health<\/em><br \/>\n          \n        <\/li>\n<li>\n          <em>Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist<\/em>\n        <\/li>\n<li>\n          <em>Both will help NexImmune advance current early-stage clinical trials and will guide Company\u2019s translational efforts to develop new immunotherapy products<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>GAITHERSBURG, Md., Jan.  04, 2021  (GLOBE NEWSWIRE) &#8212; NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the hiring of veteran biopharmaceutical industry leader Jerome (Jerry) Zeldis, MD, PhD, as Executive Vice President of Research &amp; Development and the appointment of leading immunotherapy expert Jeffrey Weber, MD, PhD, as Chief Scientific Advisor and Scientific Advisory Board Chair.<\/p>\n<p>\u201cWe are very honored to have someone of Dr. Zeldis\u2019 caliber lead our scientific research and clinical development teams. It\u2019s also rewarding to welcome a world-leading immunotherapy expert like Dr. Weber as our first Chief Scientific Advisor,\u201d stated Scott Carmer, NexImmune Chief Executive Officer (CEO). \u201cBoth Jerry and Jeff have proven and successful track records in the design and execution of early and late-stage clinical trials that have evaluated novel immune therapies. In addition, their collective research insights will greatly enhance existing efforts to translate the scientific potential of our AIM technology into therapies designed to address significant unmet patient needs.\u201d<\/p>\n<p>Dr. Zeldis, who formerly served as Chief Medical Officer (CMO) and Head of Clinical Research, Medical Affairs, and Drug Safety, at Celgene, and CEO of Celgene Global Health, helped guide Celgene\u2019s expansion into one of the biotechnology industry\u2019s most successful companies. At NexImmune, he will oversee all aspects of research and development. He brings extensive life sciences experience to the Company, gained primarily through his nearly 20-year career at Celgene where he built the medical infrastructure as the company evolved. Later as CMO and President of Clinical Research, Medical Affairs, Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc, he helped to advance its unique immuno-oncology programs.\u00a0<\/p>\n<p>Dr. Weber, who serves as deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, and co-director of its Melanoma Research Program, becomes the Company\u2019s first Chief Scientific Advisor, and will also assume the role of Scientific Advisory Board Chair. In this capacity, he will assist and advise the Company\u2019s Research and Review Committee, which is responsible for all pre-clinical and translational research in support of its proprietary AIM technology platform.\u00a0<\/p>\n<p>Dr. Weber works at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health where his primary focus is treating patients with melanoma and other cutaneous malignancies. Through his distinguished career, he has helped to pioneer development of checkpoint blockade immunotherapy strategies in melanoma, led studies into targeted therapies in melanoma, advanced understanding of potential toxicities from emerging immunotherapies, and explored novel immune therapy concepts.<\/p>\n<p>\u201cI look forward to working with Scott and his team at NexImmune to help advance and expand the Company\u2019s research and development pipeline with the ultimate goal of developing next-generation immunotherapies for patients suffering from immune-mediated conditions related to cancers and autoimmune\/inflammatory diseases,\u201d Dr. Zeldis commented.<\/p>\n<p>\u201cIt is my privilege to advise NexImmune as it seeks to develop novel treatments for melanoma and other cancers,\u201d stated Dr. Weber. \u201cWith our collective experience and commitment to improving the treatment landscape for patients, I believe we can develop and establish therapies for cancer that will make a meaningful difference to human health in the near future.\u201d<\/p>\n<p>\n        <strong>About NexImmune<\/strong><br \/>\n        <br \/>NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent, and durable immune response that mimics natural biology. The backbone of NexImmune\u2019s approach is its proprietary Artificial Immune Modulation (AIM<sup>TM<\/sup>) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune\u2019s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities.<\/p>\n<p>NexImmune\u2019s two lead programs, NEXI-001 and NEXI-002, are in Phase 1\/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to &gt;3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fElw48zKmBx5E_CP2rzXIGeh117F0iqsoN9Iu5Ge2FIw8otkzmhwrG5zvHXhRrcdLxp8XRlQ0O0uxIDB1GDQ8Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.neximmune.com<\/a>.<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Mike Beyer<br \/>Sam Brown Inc. Healthcare Communications<br \/>312-961-2502<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JmGr3hCO8RI50BIZNeWM6A_fe_tpjLaL3n3d9wxcQpakHQQoQFNyC93FA7jYKrcM1Qg6nDwLzJm9TYUCs0foR_F6MJcJuLochm9ghp2EwnI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mikebeyer@sambrown.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Chad Rubin<br \/>Solebury Trout<br \/>+1-646-378-2947<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cj3lLpZdb9tI3FsyVUwevvGSr4vgxJ4o14-Xf_t56bUz9o4m-QkdGYwWEug--X7anCsohdY35zOKPHHCsEHRDofqTKI4Ku1tmaovcb7Va5c=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">crubin@soleburytrout.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/92110d1d-de09-41eb-8c8c-93be5e0d2376\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist Both will help NexImmune advance current early-stage clinical trials and will guide Company\u2019s translational efforts to develop new immunotherapy products GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the hiring of veteran biopharmaceutical industry leader Jerome (Jerry) Zeldis, MD, PhD, as Executive Vice President of Research &amp; Development and the appointment of leading immunotherapy expert Jeffrey Weber, MD, PhD, as Chief &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist Both will help NexImmune advance current early-stage clinical trials and will guide Company\u2019s translational efforts to develop new immunotherapy products GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the hiring of veteran biopharmaceutical industry leader Jerome (Jerry) Zeldis, MD, PhD, as Executive Vice President of Research &amp; Development and the appointment of leading immunotherapy expert Jeffrey Weber, MD, PhD, as Chief &hellip; Continue reading &quot;NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T11:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor\",\"datePublished\":\"2021-01-04T11:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/\"},\"wordCount\":807,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/\",\"name\":\"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=\",\"datePublished\":\"2021-01-04T11:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/","og_locale":"en_US","og_type":"article","og_title":"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor - Market Newsdesk","og_description":"Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist Both will help NexImmune advance current early-stage clinical trials and will guide Company\u2019s translational efforts to develop new immunotherapy products GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the hiring of veteran biopharmaceutical industry leader Jerome (Jerry) Zeldis, MD, PhD, as Executive Vice President of Research &amp; Development and the appointment of leading immunotherapy expert Jeffrey Weber, MD, PhD, as Chief &hellip; Continue reading \"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T11:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor","datePublished":"2021-01-04T11:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/"},"wordCount":807,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/","name":"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=","datePublished":"2021-01-04T11:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTY1NiMzOTAyMjA1IzIwODQxOTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-strengthens-scientific-leadership-by-appointing-jerome-zeldis-as-evp-rd-and-jeffrey-weber-as-chief-scientific-advisor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&amp;D and Jeffrey Weber as Chief Scientific Advisor"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}